Mechanistic evaluation of mast cell agonists combined with TLR, NOD and STING agonists.
肥大细胞激动剂联合 TLR、NOD 和 STING 激动剂的机制评估。
基本信息
- 批准号:10657847
- 负责人:
- 金额:$ 64.52万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-01-03 至 2027-12-31
- 项目状态:未结题
- 来源:
- 关键词:AcidsAdjuvantAgonistAnaphylaxisAnimal ModelAntigen-Presenting CellsAntigensAreaAttenuatedAutoimmunityAutopsyBindingBiocompatible MaterialsBlood Chemical AnalysisCD8-Positive T-LymphocytesCategoriesCell DegranulationCellsCold ChainsContractsDataDelayed HypersensitivityDextransDoseElderlyEmulsionsEncapsulatedEnsureEnvironmentEvaluationFormulationGenesGeneticGenetic VariationGoalsHistamineHistologyHumanHydrophobicityIgEImmuneImmune responseImmune systemImmunityImmunizationImmunohistochemistryImmunologic StimulationIn VitroInbred Strains MiceInfectionKnockout MiceLangerhans cellLeukocytesLeukotrienesLipid ALiposomesLymphocyteMapsMeasuresMemoryMemory B-LymphocyteMethodsModelingMouse StrainsMusNucleotidesOvalbuminPathologyPattern recognition receptorPeptidesPopulationPopulation HeterogeneityPredispositionProductionProstaglandinsProteinsReceptor CellRecombinantsReportingResourcesSafetyScheduleSerumSeverity of illnessSiteSmallpoxStimulator of Interferon GenesSubunit VaccinesT cell responseTLR2 geneToll-like receptorsToxic effectTryptaseUnited States National Institutes of HealthVaccinationVaccine ResearchVaccinesVacciniaVaccinia VaccineViralWorkadaptive immune responseagedaging populationaluminum sulfateantigen testantigen-specific T cellscontrolled releasecytokinecytotoxicitydraining lymph nodehuman modelin vivoinsightmast cellmonocytemouse modelparticlepathogenprotective effectrecruitresponsesmall moleculesynergismtoolvaccine efficacyvaccine evaluationvaccine formulation
项目摘要
ABSTRACT
Subunit vaccines are safer and can more broadly be applied across the population then other vaccine
formulations such as live-attenuated. However, subunit antigens are often poorly antigenic and require
formulation with an immune stimulating adjuvant to garner protection. Additionally, some vaccines require more
than one adjuvant, necessitating combined adjuvants to stimulate a protective response. Also, a combined
adjuvant could decrease vaccination boosts and provide longer protection. One avenue to evaluate combined
adjuvants is with mast cell (MC) agonists. MCs are throughout the body and reside at many interfaces of the
host and the environment. When activated MCs recruit monocytes and leukocytes to the local area and help to
promote an adaptive response. MC agonists combined with toll-like receptor (TLR), nucleotide-binding
oligomerization domain-containing protein 2 (NOD-2), or stimulators of interferon genes (STING) agonists should
elicit not only a humoral response, but also a cellular response to create an efficacious and effective vaccine.
Herein we will evaluate combined MC agonists with TLR, NOD-2 or STING agonist to identify synergistic pairs.
Pairs will be evaluated in mice and human cells as well as with cells from collaborative cross (CC) strains. The
CC strains are a large panel of recombinant inbred mouse strains with genetic variation that can mimic the
human population as well as give insight into genetic variables that contribute to adjuvant mechanism. To ensure
that the adjuvants are co-delivered as well as offer dose sparring, storage outside the cold chain and controlled
release of adjuvant, we will formulate them into acetalated dextran (Ac-DEX) microparticles. Ac-DEX
formulations have illustrated enhanced delivery of STING, NOD-2, TLR and MC agonists in vitro and in vivo,
above that of other carriers like liposomes or PLGA particles. The best identified adjuvant combination will be
evaluated in a mouse model of a vaccinia vaccine with subunit antigen BR8. We will use pattern recognition
receptor (PRR) knock-out mice as well as cell deficient mice to elucidate aspects of the combination adjuvant's
mechanism. Additionally, we will employ genetic sequencing tools to mechanistically identify the combination
adjuvants mechanism.
摘要
与其他疫苗相比,亚单位疫苗更安全,可以更广泛地应用于人群
活体减毒等制剂。然而,亚单位抗原通常抗原性较差,需要
含有免疫刺激佐剂的配方以获得保护。此外,一些疫苗需要更多
而不是一种佐剂,需要联合佐剂来刺激保护性反应。此外,合并后的
佐剂可以减少疫苗接种次数,并提供更长时间的保护。综合评价的一种途径
佐剂使用肥大细胞(MC)激动剂。MCS遍布全身,驻留在
主机和环境。当被激活时,MC将单核细胞和白细胞招募到局部区域,并帮助
促进适应性反应。MC激动剂与Toll样受体(TLR)结合,核苷酸结合
低聚含结构域蛋白2(NOD-2)或干扰素基因刺激物(STIN)激动剂应
不仅引起体液反应,还引起细胞反应,以创造出有效和有效的疫苗。
在这里,我们将评估MC激动剂与TLR、NOD-2或STING激动剂的联合作用,以确定协同作用对。
配对将在小鼠和人类细胞以及来自协作杂交(CC)菌株的细胞中进行评估。这个
CC品系是一大批具有遗传变异的重组近交系小鼠品系,可以模仿
并提供了对佐剂机制有贡献的遗传变量的见解。为了确保
佐剂是联合递送的,并提供剂量辩论、冷链之外的储存和受控
释放佐剂后,我们将它们制成乙缩醛葡聚糖(Ac-DEX)微粒。AC-DEX
制剂表明,在体外和体内,STIN、NOD-2、TLR和MC激动剂的释放增加,
高于其他载体,如脂质体或PLGA颗粒。最好的佐剂组合将是
在含有BR8亚单位抗原的牛痘疫苗的小鼠模型中进行评估。我们将使用模式识别
受体(PRR)敲除小鼠以及细胞缺陷小鼠,以阐明联合佐剂的某些方面
机制。此外,我们将使用基因测序工具来机械地识别这种组合
佐剂机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kristy M Ainslie其他文献
Kristy M Ainslie的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kristy M Ainslie', 18)}}的其他基金
Tunable Temporal Drug Release for Optimized Synergistic Combination Therapy of Glioblastoma
可调节的时间药物释放,用于优化胶质母细胞瘤的协同联合治疗
- 批准号:
10449370 - 财政年份:2021
- 资助金额:
$ 64.52万 - 项目类别:
Diversity Supplement - Formulation to Generate Tolerance Towards Type 1 Diabetes
多样性补充剂 - 产生对 1 型糖尿病耐受性的配方
- 批准号:
10560761 - 财政年份:2021
- 资助金额:
$ 64.52万 - 项目类别:
Formulation to Generate Tolerance Towards Type 1 Diabetes
产生对 1 型糖尿病耐受性的配方
- 批准号:
10436981 - 财政年份:2021
- 资助金额:
$ 64.52万 - 项目类别:
Formulation to Generate Tolerance Towards Type 1 Diabetes
产生对 1 型糖尿病耐受性的配方
- 批准号:
10713401 - 财政年份:2021
- 资助金额:
$ 64.52万 - 项目类别:
Formulation to Generate Tolerance Towards Type 1 Diabetes
产生对 1 型糖尿病耐受性的配方
- 批准号:
10310642 - 财政年份:2021
- 资助金额:
$ 64.52万 - 项目类别:
Tunable Temporal Drug Release for Optimized Synergistic Combination Therapy of Glioblastoma
可调节的时间药物释放,用于优化胶质母细胞瘤的协同联合治疗
- 批准号:
10675073 - 财政年份:2021
- 资助金额:
$ 64.52万 - 项目类别:
Formulation to Generate Tolerance Towards Type 1 Diabetes
产生对 1 型糖尿病耐受性的配方
- 批准号:
10615119 - 财政年份:2021
- 资助金额:
$ 64.52万 - 项目类别:
Tunable Temporal Drug Release for Optimized Synergistic Combination Therapy of Glioblastoma
可调节的时间药物释放,用于优化胶质母细胞瘤的协同联合治疗
- 批准号:
10309049 - 财政年份:2021
- 资助金额:
$ 64.52万 - 项目类别:
Optimizing a Universal Influenza Subunit Nano/Microparticulate Vaccine
优化通用流感亚单位纳米/微粒疫苗
- 批准号:
10328236 - 财政年份:2020
- 资助金额:
$ 64.52万 - 项目类别:
Optimizing a Universal Influenza Subunit Nano/Microparticulate Vaccine
优化通用流感亚单位纳米/微粒疫苗
- 批准号:
10540741 - 财政年份:2020
- 资助金额:
$ 64.52万 - 项目类别:
相似海外基金
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 64.52万 - 项目类别:
Augmenting the Quality and Duration of the Immune Response with a Novel TLR2 Agonist-Aluminum Combination Adjuvant
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10499193 - 财政年份:2021
- 资助金额:
$ 64.52万 - 项目类别:
A Novel TLR5 Agonist-Based Adjuvant for Poliovirus Vaccine
一种基于 TLR5 激动剂的新型脊髓灰质炎病毒疫苗佐剂
- 批准号:
9305008 - 财政年份:2016
- 资助金额:
$ 64.52万 - 项目类别:
Angiogenesis antagonist plus CD40-TLR agonist adjuvant combination vaccine
血管生成拮抗剂加CD40-TLR激动剂佐剂组合疫苗
- 批准号:
8054408 - 财政年份:2010
- 资助金额:
$ 64.52万 - 项目类别:
Angiogenesis antagonist plus CD40-TLR agonist adjuvant combination vaccine
血管生成拮抗剂加CD40-TLR激动剂佐剂组合疫苗
- 批准号:
7909550 - 财政年份:2010
- 资助金额:
$ 64.52万 - 项目类别:
Malaria vaccines modified with TLR agonist adjuvant
TLR 激动剂佐剂修饰的疟疾疫苗
- 批准号:
8126073 - 财政年份:2010
- 资助金额:
$ 64.52万 - 项目类别:
Malaria vaccines modified with TLR agonist adjuvant
TLR 激动剂佐剂修饰的疟疾疫苗
- 批准号:
7899536 - 财政年份:2009
- 资助金额:
$ 64.52万 - 项目类别:
C5a Agonist as a Vaccine Adjuvant for the Aged
C5a 激动剂作为老年人的疫苗佐剂
- 批准号:
7362543 - 财政年份:2007
- 资助金额:
$ 64.52万 - 项目类别:
C5a Agonist as a Vaccine Adjuvant for the Aged
C5a 激动剂作为老年人的疫苗佐剂
- 批准号:
7502193 - 财政年份:2007
- 资助金额:
$ 64.52万 - 项目类别:
C5a Agonist as a Vaccine Adjuvant for the Aged
C5a 激动剂作为老年人的疫苗佐剂
- 批准号:
7911043 - 财政年份:2007
- 资助金额:
$ 64.52万 - 项目类别:














{{item.name}}会员




